Literature DB >> 15365007

Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay.

Hongmei Mo1, Liangjun Lu, Ron Pithawalla, Dale J Kempf, Akhteruzzaman Molla.   

Abstract

The impact of cotransfection of mixtures of mutant and wild type (WT) virus on the observed phenotype and replication capacity (RC) in a single-cycle human immunodeficiency virus (HIV) phenotypic assay has been investigated by cotransfecting mutant HIV clones expressing the firefly luciferase expression gene with a WT clone expressing Renilla luciferase. Four mutant constructs with different genotypes displayed <1% RC when transfected alone. Cotransfection of as little as 9% of the WT clone resulted in an 18- to 33-fold increase in the RC of the mutant clones. In addition, the 50% inhibitory concentration (IC(50)) of lopinavir against seven mutant clones decreased by up to 97% after incremental cotransfection of 9 to 50% of the WT clone. The enhancement of RC and decrease in IC(50) for mutant variants following cotransfection with the WT variant appear to be due to complementation rather than genetic recombination. These findings suggest that the RC and susceptibility of plasma isolates from patients who are off therapy or not adherent to treatment, in which WT virus may expand to significant levels, should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365007      PMCID: PMC516276          DOI: 10.1128/JCM.42.9.4169-4174.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Authors:  M Nijhuis; R Schuurman; D de Jong; J Erickson; E Gustchina; J Albert; P Schipper; S Gulnik; C A Boucher
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

2.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

Review 3.  Update on antiretroviral drug resistance testing: combining laboratory technology with patient care.

Authors:  John W Wilson
Journal:  AIDS Read       Date:  2003-01

4.  Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.

Authors:  Stefano Menzo; Alessia Monachetti; Claudia Balotta; Stefano Corvasce; Stefano Rusconi; Stefania Paolucci; Fausto Baldanti; Patrizia Bagnarelli; Massimo Clementi
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

5.  Modulation of the affinity of aspartic proteases by the mutated residues in active site models.

Authors:  A Goldblum
Journal:  FEBS Lett       Date:  1990-02-26       Impact factor: 4.124

6.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Viral interference in HIV-1 infected cells.

Authors: 
Journal:  Rev Med Virol       Date:  1998-10       Impact factor: 6.989

Review 8.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

9.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  3 in total

1.  MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.

Authors:  Evguenia S Svarovskaia; Michael J Moser; Andrew S Bae; James R Prudent; Michael D Miller; Katyna Borroto-Esoda
Journal:  J Clin Microbiol       Date:  2006-09-27       Impact factor: 5.948

2.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

3.  Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

Authors:  Tatyana Dekhtyar; Teresa I Ng; Liangjun Lu; Sherie Masse; David A DeGoey; William J Flosi; David J Grampovnik; Larry L Klein; Dale J Kempf; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.